Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 3/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | AKT2 | P31751 | 1/20 | 0.49 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388380 | 1.00 | NOX4 (0.60) | NOX4GSK3BERBB2DHFRRET | |
| SCHEMBL6390614 | 0.93 | NOX4 (0.60) | NOX4GSK3BERBB2RETLRRK2 | |
| SCHEMBL6390621 | 0.93 | NOX4 (0.60) | NOX4GSK3BERBB2RETLRRK2 | |
| SCHEMBL7989495 | 0.90 | NOX4 (0.51) | NOX4GSK3BERBB2DHFRRET | |
| SCHEMBL7989491 | 0.90 | NOX4 (0.51) | NOX4GSK3BERBB2DHFRRET | |
| SCHEMBL7717894 | 0.85 | GSK3B (0.52) | NOX4GSK3BERBB2DHFRRET | |
| SCHEMBL6408143 | 0.84 | ERBB2 (0.69) | ERBB2DHFRRETPLK4PLK1 | |
| SCHEMBL6396491 | 0.84 | ERBB2 (0.69) | ERBB2DHFRRETPLK4PLK1 | |
| SCHEMBL8001367 | 0.80 | ERBB2 (0.64) | ERBB2DHFRPLK4PLK1CSNK1D | |
| SCHEMBL8001370 | 0.80 | ERBB2 (0.64) | ERBB2DHFRPLK4PLK1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | claimed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | claimed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | NOX4 2595/4885GSK3B 419/4885ERBB2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.